Keveyis® (dichlorphenamide)

About Xeris Pharmaceuticals

Xeris Pharmaceuticals' mission is to develop and commercialize novel, ready-to-use injectable drug formulations that overcome stability and delivery challenges. The company has successfully leveraged its proprietary technology platforms to bring multiple products to market, including Gvoke® for severe hypoglycemia and Keveyis® for primary periodic paralysis. Its strategy focuses on expanding its commercial portfolio, advancing a deep pipeline of 19+ candidates, and forming strategic partnerships to apply its formulation expertise to a broad range of therapeutics. Xeris operates as an integrated biopharma company, controlling development, manufacturing, and commercialization.

Therapeutic Areas